Global mRNA, biologics manufacturing gaining momentum

Concerns about global inequities in access to COVID-19 vaccines and therapies are prompting international organizations, governments in developing countries, and biopharmaceutical companies to invest in manufacturing capabilities in low- and middle-income countries. In the long term, these investments could improve access to medicines, including for neglected diseases that are prevalent primarily in developing countries, and increase global resiliency against future pandemics. 

WHO has launched initiatives to enhance biomanufacturing capabilities in low- and middle-income countries, including by supporting mRNA vaccine R&D and setting up manufacturing facilities and creating a global training facility in South Korea. ...